nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—CES1—Capecitabine—kidney cancer	0.216	0.468	CbGbCtD
Dabigatran etexilate—ABCB1—kidney cancer	0.192	1	CbGaD
Dabigatran etexilate—UGT1A9—Sorafenib—kidney cancer	0.0729	0.158	CbGbCtD
Dabigatran etexilate—ABCB1—Temsirolimus—kidney cancer	0.0388	0.0842	CbGbCtD
Dabigatran etexilate—F2—posterior vena cava—kidney cancer	0.0288	0.404	CbGeAlD
Dabigatran etexilate—ABCB1—Pazopanib—kidney cancer	0.0204	0.0442	CbGbCtD
Dabigatran etexilate—ABCB1—Dactinomycin—kidney cancer	0.0186	0.0404	CbGbCtD
Dabigatran etexilate—ABCB1—Gemcitabine—kidney cancer	0.0147	0.032	CbGbCtD
Dabigatran etexilate—ABCB1—Erlotinib—kidney cancer	0.0145	0.0315	CbGbCtD
Dabigatran etexilate—ABCB1—Paclitaxel—kidney cancer	0.0133	0.0289	CbGbCtD
Dabigatran etexilate—ABCB1—Sorafenib—kidney cancer	0.0118	0.0257	CbGbCtD
Dabigatran etexilate—ABCB1—Vinblastine—kidney cancer	0.0117	0.0253	CbGbCtD
Dabigatran etexilate—ABCB1—Vincristine—kidney cancer	0.0115	0.0249	CbGbCtD
Dabigatran etexilate—ABCB1—Sunitinib—kidney cancer	0.00958	0.0208	CbGbCtD
Dabigatran etexilate—F2—urine—kidney cancer	0.00745	0.104	CbGeAlD
Dabigatran etexilate—ABCB1—Doxorubicin—kidney cancer	0.00717	0.0156	CbGbCtD
Dabigatran etexilate—UGT1A9—renal system—kidney cancer	0.00252	0.0353	CbGeAlD
Dabigatran etexilate—UGT1A9—kidney—kidney cancer	0.00244	0.0341	CbGeAlD
Dabigatran etexilate—CES2—nephron tubule—kidney cancer	0.00224	0.0313	CbGeAlD
Dabigatran etexilate—CES2—renal system—kidney cancer	0.00203	0.0285	CbGeAlD
Dabigatran etexilate—UGT2B7—renal system—kidney cancer	0.00203	0.0285	CbGeAlD
Dabigatran etexilate—NQO2—nephron tubule—kidney cancer	0.002	0.028	CbGeAlD
Dabigatran etexilate—CES2—kidney—kidney cancer	0.00196	0.0275	CbGeAlD
Dabigatran etexilate—UGT2B7—kidney—kidney cancer	0.00196	0.0275	CbGeAlD
Dabigatran etexilate—CES2—cortex of kidney—kidney cancer	0.00191	0.0268	CbGeAlD
Dabigatran etexilate—F2—renal system—kidney cancer	0.00182	0.0255	CbGeAlD
Dabigatran etexilate—CES2—gonad—kidney cancer	0.00182	0.0255	CbGeAlD
Dabigatran etexilate—CES2—cardiac atrium—kidney cancer	0.00182	0.0255	CbGeAlD
Dabigatran etexilate—NQO2—renal system—kidney cancer	0.00182	0.0254	CbGeAlD
Dabigatran etexilate—F2—kidney—kidney cancer	0.00176	0.0247	CbGeAlD
Dabigatran etexilate—NQO2—kidney—kidney cancer	0.00176	0.0246	CbGeAlD
Dabigatran etexilate—NQO2—cortex of kidney—kidney cancer	0.00171	0.0239	CbGeAlD
Dabigatran etexilate—NQO2—cardiac atrium—kidney cancer	0.00163	0.0228	CbGeAlD
Dabigatran etexilate—ABCB1—nephron tubule—kidney cancer	0.000431	0.00604	CbGeAlD
Dabigatran etexilate—ABCB1—renal system—kidney cancer	0.000392	0.00549	CbGeAlD
Dabigatran etexilate—ABCB1—kidney—kidney cancer	0.000379	0.00531	CbGeAlD
Dabigatran etexilate—ABCB1—cortex of kidney—kidney cancer	0.000369	0.00517	CbGeAlD
Dabigatran etexilate—ABCB1—gonad—kidney cancer	0.000351	0.00492	CbGeAlD
Dabigatran etexilate—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000132	0.00064	CcSEcCtD
Dabigatran etexilate—Urticaria—Sorafenib—kidney cancer	0.000131	0.000638	CcSEcCtD
Dabigatran etexilate—Haematuria—Capecitabine—kidney cancer	0.000131	0.000637	CcSEcCtD
Dabigatran etexilate—Malnutrition—Paclitaxel—kidney cancer	0.000131	0.000636	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vinblastine—kidney cancer	0.000131	0.000636	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Sorafenib—kidney cancer	0.000131	0.000635	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Everolimus—kidney cancer	0.00013	0.000633	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Sunitinib—kidney cancer	0.00013	0.000632	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Capecitabine—kidney cancer	0.00013	0.000632	CcSEcCtD
Dabigatran etexilate—Pruritus—Erlotinib—kidney cancer	0.00013	0.000632	CcSEcCtD
Dabigatran etexilate—Fatigue—Dactinomycin—kidney cancer	0.00013	0.000631	CcSEcCtD
Dabigatran etexilate—Epistaxis—Capecitabine—kidney cancer	0.00013	0.00063	CcSEcCtD
Dabigatran etexilate—Flatulence—Paclitaxel—kidney cancer	0.000129	0.000627	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Gemcitabine—kidney cancer	0.000128	0.00062	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Doxorubicin—kidney cancer	0.000127	0.000616	CcSEcCtD
Dabigatran etexilate—Infection—Gemcitabine—kidney cancer	0.000127	0.000616	CcSEcCtD
Dabigatran etexilate—Back pain—Paclitaxel—kidney cancer	0.000127	0.000616	CcSEcCtD
Dabigatran etexilate—Dizziness—Vinblastine—kidney cancer	0.000126	0.000614	CcSEcCtD
Dabigatran etexilate—Dizziness—Everolimus—kidney cancer	0.000126	0.000612	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Sunitinib—kidney cancer	0.000126	0.000611	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Erlotinib—kidney cancer	0.000126	0.000611	CcSEcCtD
Dabigatran etexilate—Hypotension—Vincristine—kidney cancer	0.000126	0.000611	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Gemcitabine—kidney cancer	0.000125	0.000608	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Gemcitabine—kidney cancer	0.000125	0.000607	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Capecitabine—kidney cancer	0.000124	0.000603	CcSEcCtD
Dabigatran etexilate—Skin disorder—Gemcitabine—kidney cancer	0.000124	0.000603	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Capecitabine—kidney cancer	0.000124	0.0006	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000123	0.000598	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000123	0.000596	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Capecitabine—kidney cancer	0.000122	0.000592	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Sorafenib—kidney cancer	0.000122	0.000592	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Capecitabine—kidney cancer	0.000122	0.000591	CcSEcCtD
Dabigatran etexilate—Vomiting—Vinblastine—kidney cancer	0.000122	0.000591	CcSEcCtD
Dabigatran etexilate—Dizziness—Erlotinib—kidney cancer	0.000122	0.000591	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Capecitabine—kidney cancer	0.000121	0.00059	CcSEcCtD
Dabigatran etexilate—Vomiting—Everolimus—kidney cancer	0.000121	0.000588	CcSEcCtD
Dabigatran etexilate—Anaemia—Paclitaxel—kidney cancer	0.000121	0.000588	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Capecitabine—kidney cancer	0.000121	0.000588	CcSEcCtD
Dabigatran etexilate—Rash—Everolimus—kidney cancer	0.00012	0.000584	CcSEcCtD
Dabigatran etexilate—Dermatitis—Everolimus—kidney cancer	0.00012	0.000583	CcSEcCtD
Dabigatran etexilate—Headache—Vinblastine—kidney cancer	0.00012	0.000582	CcSEcCtD
Dabigatran etexilate—Angioedema—Paclitaxel—kidney cancer	0.00012	0.000581	CcSEcCtD
Dabigatran etexilate—Headache—Everolimus—kidney cancer	0.000119	0.00058	CcSEcCtD
Dabigatran etexilate—Hypotension—Gemcitabine—kidney cancer	0.000119	0.00058	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dactinomycin—kidney cancer	0.000119	0.000579	CcSEcCtD
Dabigatran etexilate—Asthenia—Sorafenib—kidney cancer	0.000119	0.000576	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Doxorubicin—kidney cancer	0.000118	0.000573	CcSEcCtD
Dabigatran etexilate—Syncope—Paclitaxel—kidney cancer	0.000117	0.000571	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Sunitinib—kidney cancer	0.000117	0.00057	CcSEcCtD
Dabigatran etexilate—Pruritus—Sorafenib—kidney cancer	0.000117	0.000568	CcSEcCtD
Dabigatran etexilate—Vomiting—Erlotinib—kidney cancer	0.000117	0.000568	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000116	0.000565	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Vincristine—kidney cancer	0.000116	0.000565	CcSEcCtD
Dabigatran etexilate—Fatigue—Vincristine—kidney cancer	0.000116	0.000564	CcSEcCtD
Dabigatran etexilate—Rash—Erlotinib—kidney cancer	0.000116	0.000563	CcSEcCtD
Dabigatran etexilate—Dermatitis—Erlotinib—kidney cancer	0.000116	0.000563	CcSEcCtD
Dabigatran etexilate—Palpitations—Paclitaxel—kidney cancer	0.000116	0.000562	CcSEcCtD
Dabigatran etexilate—Headache—Erlotinib—kidney cancer	0.000115	0.000559	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Paclitaxel—kidney cancer	0.000115	0.000559	CcSEcCtD
Dabigatran etexilate—Constipation—Vincristine—kidney cancer	0.000115	0.000559	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	0.000115	0.000559	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—kidney cancer	0.000115	0.000559	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—kidney cancer	0.000115	0.000559	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Capecitabine—kidney cancer	0.000115	0.000557	CcSEcCtD
Dabigatran etexilate—Cough—Paclitaxel—kidney cancer	0.000114	0.000555	CcSEcCtD
Dabigatran etexilate—Asthenia—Sunitinib—kidney cancer	0.000114	0.000555	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Gemcitabine—kidney cancer	0.000114	0.000553	CcSEcCtD
Dabigatran etexilate—Nausea—Vinblastine—kidney cancer	0.000114	0.000552	CcSEcCtD
Dabigatran etexilate—Nausea—Everolimus—kidney cancer	0.000113	0.00055	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Sorafenib—kidney cancer	0.000113	0.00055	CcSEcCtD
Dabigatran etexilate—Hypertension—Paclitaxel—kidney cancer	0.000113	0.000549	CcSEcCtD
Dabigatran etexilate—Pruritus—Sunitinib—kidney cancer	0.000113	0.000547	CcSEcCtD
Dabigatran etexilate—Angiopathy—Capecitabine—kidney cancer	0.000112	0.000544	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Capecitabine—kidney cancer	0.000112	0.000542	CcSEcCtD
Dabigatran etexilate—Arthralgia—Paclitaxel—kidney cancer	0.000112	0.000542	CcSEcCtD
Dabigatran etexilate—Chest pain—Paclitaxel—kidney cancer	0.000112	0.000542	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Capecitabine—kidney cancer	0.000111	0.000541	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Dactinomycin—kidney cancer	0.000111	0.000539	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000111	0.000538	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00011	0.000536	CcSEcCtD
Dabigatran etexilate—Fatigue—Gemcitabine—kidney cancer	0.00011	0.000535	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Vincristine—kidney cancer	0.00011	0.000535	CcSEcCtD
Dabigatran etexilate—Dizziness—Sorafenib—kidney cancer	0.000109	0.000531	CcSEcCtD
Dabigatran etexilate—Constipation—Gemcitabine—kidney cancer	0.000109	0.00053	CcSEcCtD
Dabigatran etexilate—Nausea—Erlotinib—kidney cancer	0.000109	0.00053	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Sunitinib—kidney cancer	0.000109	0.000529	CcSEcCtD
Dabigatran etexilate—Asthenia—Dactinomycin—kidney cancer	0.000108	0.000525	CcSEcCtD
Dabigatran etexilate—Malnutrition—Capecitabine—kidney cancer	0.000108	0.000522	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Paclitaxel—kidney cancer	0.000107	0.000519	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Vincristine—kidney cancer	0.000106	0.000517	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—kidney cancer	0.000106	0.000516	CcSEcCtD
Dabigatran etexilate—Infection—Paclitaxel—kidney cancer	0.000106	0.000516	CcSEcCtD
Dabigatran etexilate—Flatulence—Capecitabine—kidney cancer	0.000106	0.000515	CcSEcCtD
Dabigatran etexilate—Dizziness—Sunitinib—kidney cancer	0.000105	0.000511	CcSEcCtD
Dabigatran etexilate—Shock—Paclitaxel—kidney cancer	0.000105	0.000511	CcSEcCtD
Dabigatran etexilate—Vomiting—Sorafenib—kidney cancer	0.000105	0.000511	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—kidney cancer	0.000105	0.000511	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Paclitaxel—kidney cancer	0.000105	0.000509	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Paclitaxel—kidney cancer	0.000105	0.000509	CcSEcCtD
Dabigatran etexilate—Rash—Sorafenib—kidney cancer	0.000104	0.000507	CcSEcCtD
Dabigatran etexilate—Dermatitis—Sorafenib—kidney cancer	0.000104	0.000506	CcSEcCtD
Dabigatran etexilate—Back pain—Capecitabine—kidney cancer	0.000104	0.000505	CcSEcCtD
Dabigatran etexilate—Skin disorder—Paclitaxel—kidney cancer	0.000104	0.000504	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000104	0.000503	CcSEcCtD
Dabigatran etexilate—Headache—Sorafenib—kidney cancer	0.000104	0.000503	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dactinomycin—kidney cancer	0.000103	0.000501	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—kidney cancer	0.000103	0.0005	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—kidney cancer	0.000102	0.000495	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000101	0.000493	CcSEcCtD
Dabigatran etexilate—Vomiting—Sunitinib—kidney cancer	0.000101	0.000492	CcSEcCtD
Dabigatran etexilate—Rash—Sunitinib—kidney cancer	0.0001	0.000487	CcSEcCtD
Dabigatran etexilate—Dermatitis—Sunitinib—kidney cancer	0.0001	0.000487	CcSEcCtD
Dabigatran etexilate—Hypotension—Paclitaxel—kidney cancer	9.99e-05	0.000485	CcSEcCtD
Dabigatran etexilate—Headache—Sunitinib—kidney cancer	9.97e-05	0.000484	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—kidney cancer	9.95e-05	0.000483	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—kidney cancer	9.95e-05	0.000483	CcSEcCtD
Dabigatran etexilate—Anaemia—Capecitabine—kidney cancer	9.94e-05	0.000483	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Vincristine—kidney cancer	9.92e-05	0.000482	CcSEcCtD
Dabigatran etexilate—Nausea—Sorafenib—kidney cancer	9.82e-05	0.000477	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Paclitaxel—kidney cancer	9.74e-05	0.000473	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—kidney cancer	9.69e-05	0.000471	CcSEcCtD
Dabigatran etexilate—Asthenia—Vincristine—kidney cancer	9.66e-05	0.000469	CcSEcCtD
Dabigatran etexilate—Syncope—Capecitabine—kidney cancer	9.64e-05	0.000468	CcSEcCtD
Dabigatran etexilate—Vomiting—Dactinomycin—kidney cancer	9.58e-05	0.000465	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—kidney cancer	9.57e-05	0.000465	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Paclitaxel—kidney cancer	9.53e-05	0.000463	CcSEcCtD
Dabigatran etexilate—Palpitations—Capecitabine—kidney cancer	9.5e-05	0.000461	CcSEcCtD
Dabigatran etexilate—Rash—Dactinomycin—kidney cancer	9.5e-05	0.000461	CcSEcCtD
Dabigatran etexilate—Nausea—Sunitinib—kidney cancer	9.45e-05	0.000459	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Capecitabine—kidney cancer	9.45e-05	0.000459	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Paclitaxel—kidney cancer	9.41e-05	0.000457	CcSEcCtD
Dabigatran etexilate—Cough—Capecitabine—kidney cancer	9.38e-05	0.000456	CcSEcCtD
Dabigatran etexilate—Hypertension—Capecitabine—kidney cancer	9.28e-05	0.000451	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—kidney cancer	9.24e-05	0.000449	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Paclitaxel—kidney cancer	9.23e-05	0.000448	CcSEcCtD
Dabigatran etexilate—Fatigue—Paclitaxel—kidney cancer	9.22e-05	0.000448	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vincristine—kidney cancer	9.21e-05	0.000447	CcSEcCtD
Dabigatran etexilate—Asthenia—Gemcitabine—kidney cancer	9.16e-05	0.000445	CcSEcCtD
Dabigatran etexilate—Arthralgia—Capecitabine—kidney cancer	9.15e-05	0.000445	CcSEcCtD
Dabigatran etexilate—Chest pain—Capecitabine—kidney cancer	9.15e-05	0.000445	CcSEcCtD
Dabigatran etexilate—Constipation—Paclitaxel—kidney cancer	9.14e-05	0.000444	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	9.09e-05	0.000442	CcSEcCtD
Dabigatran etexilate—Pruritus—Gemcitabine—kidney cancer	9.04e-05	0.000439	CcSEcCtD
Dabigatran etexilate—Nausea—Dactinomycin—kidney cancer	8.95e-05	0.000435	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—kidney cancer	8.92e-05	0.000433	CcSEcCtD
Dabigatran etexilate—Dizziness—Vincristine—kidney cancer	8.9e-05	0.000432	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—kidney cancer	8.87e-05	0.000431	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—kidney cancer	8.87e-05	0.000431	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Paclitaxel—kidney cancer	8.74e-05	0.000425	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Gemcitabine—kidney cancer	8.74e-05	0.000424	CcSEcCtD
Dabigatran etexilate—Infection—Capecitabine—kidney cancer	8.72e-05	0.000423	CcSEcCtD
Dabigatran etexilate—Shock—Capecitabine—kidney cancer	8.63e-05	0.000419	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—kidney cancer	8.62e-05	0.000419	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Capecitabine—kidney cancer	8.6e-05	0.000418	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Capecitabine—kidney cancer	8.59e-05	0.000417	CcSEcCtD
Dabigatran etexilate—Vomiting—Vincristine—kidney cancer	8.56e-05	0.000416	CcSEcCtD
Dabigatran etexilate—Skin disorder—Capecitabine—kidney cancer	8.52e-05	0.000414	CcSEcCtD
Dabigatran etexilate—Urticaria—Paclitaxel—kidney cancer	8.49e-05	0.000413	CcSEcCtD
Dabigatran etexilate—Rash—Vincristine—kidney cancer	8.49e-05	0.000412	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vincristine—kidney cancer	8.48e-05	0.000412	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—kidney cancer	8.46e-05	0.000411	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Paclitaxel—kidney cancer	8.45e-05	0.000411	CcSEcCtD
Dabigatran etexilate—Headache—Vincristine—kidney cancer	8.43e-05	0.00041	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—kidney cancer	8.39e-05	0.000407	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—kidney cancer	8.36e-05	0.000406	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—kidney cancer	8.32e-05	0.000404	CcSEcCtD
Dabigatran etexilate—Hypotension—Capecitabine—kidney cancer	8.2e-05	0.000398	CcSEcCtD
Dabigatran etexilate—Vomiting—Gemcitabine—kidney cancer	8.12e-05	0.000394	CcSEcCtD
Dabigatran etexilate—Rash—Gemcitabine—kidney cancer	8.05e-05	0.000391	CcSEcCtD
Dabigatran etexilate—Dermatitis—Gemcitabine—kidney cancer	8.04e-05	0.000391	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—kidney cancer	8e-05	0.000389	CcSEcCtD
Dabigatran etexilate—Headache—Gemcitabine—kidney cancer	8e-05	0.000389	CcSEcCtD
Dabigatran etexilate—Nausea—Vincristine—kidney cancer	8e-05	0.000388	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Capecitabine—kidney cancer	7.99e-05	0.000388	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—kidney cancer	7.96e-05	0.000387	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Paclitaxel—kidney cancer	7.88e-05	0.000383	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—kidney cancer	7.86e-05	0.000382	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—kidney cancer	7.84e-05	0.000381	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—kidney cancer	7.82e-05	0.00038	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Capecitabine—kidney cancer	7.82e-05	0.00038	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—kidney cancer	7.8e-05	0.000379	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Capecitabine—kidney cancer	7.72e-05	0.000375	CcSEcCtD
Dabigatran etexilate—Asthenia—Paclitaxel—kidney cancer	7.67e-05	0.000373	CcSEcCtD
Dabigatran etexilate—Nausea—Gemcitabine—kidney cancer	7.59e-05	0.000368	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Capecitabine—kidney cancer	7.58e-05	0.000368	CcSEcCtD
Dabigatran etexilate—Fatigue—Capecitabine—kidney cancer	7.56e-05	0.000367	CcSEcCtD
Dabigatran etexilate—Pruritus—Paclitaxel—kidney cancer	7.56e-05	0.000367	CcSEcCtD
Dabigatran etexilate—Constipation—Capecitabine—kidney cancer	7.5e-05	0.000364	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—kidney cancer	7.39e-05	0.000359	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Paclitaxel—kidney cancer	7.32e-05	0.000355	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—kidney cancer	7.22e-05	0.000351	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—kidney cancer	7.19e-05	0.000349	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Capecitabine—kidney cancer	7.17e-05	0.000349	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—kidney cancer	7.17e-05	0.000349	CcSEcCtD
Dabigatran etexilate—Dizziness—Paclitaxel—kidney cancer	7.07e-05	0.000343	CcSEcCtD
Dabigatran etexilate—Urticaria—Capecitabine—kidney cancer	6.97e-05	0.000339	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Capecitabine—kidney cancer	6.94e-05	0.000337	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—kidney cancer	6.93e-05	0.000337	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—kidney cancer	6.83e-05	0.000332	CcSEcCtD
Dabigatran etexilate—Vomiting—Paclitaxel—kidney cancer	6.8e-05	0.00033	CcSEcCtD
Dabigatran etexilate—Rash—Paclitaxel—kidney cancer	6.74e-05	0.000327	CcSEcCtD
Dabigatran etexilate—Dermatitis—Paclitaxel—kidney cancer	6.74e-05	0.000327	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—kidney cancer	6.7e-05	0.000326	CcSEcCtD
Dabigatran etexilate—Headache—Paclitaxel—kidney cancer	6.7e-05	0.000325	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Capecitabine—kidney cancer	6.46e-05	0.000314	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—kidney cancer	6.41e-05	0.000311	CcSEcCtD
Dabigatran etexilate—Nausea—Paclitaxel—kidney cancer	6.35e-05	0.000308	CcSEcCtD
Dabigatran etexilate—Asthenia—Capecitabine—kidney cancer	6.3e-05	0.000306	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—kidney cancer	6.21e-05	0.000302	CcSEcCtD
Dabigatran etexilate—Pruritus—Capecitabine—kidney cancer	6.21e-05	0.000302	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—kidney cancer	6.12e-05	0.000297	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—kidney cancer	6.09e-05	0.000296	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—kidney cancer	6.05e-05	0.000294	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Capecitabine—kidney cancer	6e-05	0.000292	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—kidney cancer	5.98e-05	0.000291	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—kidney cancer	5.9e-05	0.000287	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—kidney cancer	5.9e-05	0.000287	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	5.86e-05	0.000285	CcSEcCtD
Dabigatran etexilate—Dizziness—Capecitabine—kidney cancer	5.8e-05	0.000282	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—PDHB—kidney cancer	5.75e-05	0.000825	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—POMC—kidney cancer	5.73e-05	0.000823	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IFNA1—kidney cancer	5.7e-05	0.000819	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—kidney cancer	5.66e-05	0.000275	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—kidney cancer	5.62e-05	0.000273	CcSEcCtD
Dabigatran etexilate—Vomiting—Capecitabine—kidney cancer	5.58e-05	0.000271	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—ACHE—kidney cancer	5.57e-05	0.0008	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SCARB1—kidney cancer	5.57e-05	0.000799	CbGpPWpGaD
Dabigatran etexilate—Shock—Doxorubicin—kidney cancer	5.56e-05	0.00027	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—kidney cancer	5.55e-05	0.000269	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—kidney cancer	5.54e-05	0.000269	CcSEcCtD
Dabigatran etexilate—Rash—Capecitabine—kidney cancer	5.53e-05	0.000269	CcSEcCtD
Dabigatran etexilate—Dermatitis—Capecitabine—kidney cancer	5.53e-05	0.000268	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS1—kidney cancer	5.51e-05	0.000791	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—EIF4EBP1—kidney cancer	5.51e-05	0.000791	CbGpPWpGaD
Dabigatran etexilate—Headache—Capecitabine—kidney cancer	5.5e-05	0.000267	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—kidney cancer	5.49e-05	0.000267	CcSEcCtD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	5.42e-05	0.000779	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CCBL1—kidney cancer	5.41e-05	0.000776	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PSMD7—kidney cancer	5.41e-05	0.000776	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AMER1—kidney cancer	5.39e-05	0.000774	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	5.37e-05	0.000771	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—FH—kidney cancer	5.36e-05	0.00077	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APRT—kidney cancer	5.36e-05	0.00077	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IFNA2—kidney cancer	5.31e-05	0.000762	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—PAX6—kidney cancer	5.3e-05	0.000761	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Doxorubicin—kidney cancer	5.29e-05	0.000257	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—CTSD—kidney cancer	5.28e-05	0.000757	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKAP13—kidney cancer	5.24e-05	0.000753	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	5.22e-05	0.000749	CbGpPWpGaD
Dabigatran etexilate—Nausea—Capecitabine—kidney cancer	5.21e-05	0.000253	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—kidney cancer	5.15e-05	0.00025	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—BCHE—kidney cancer	5.13e-05	0.000736	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—RAF1—kidney cancer	5.1e-05	0.000733	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SLC5A5—kidney cancer	5.06e-05	0.000727	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—MAPK3—kidney cancer	5.04e-05	0.000724	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Doxorubicin—kidney cancer	5.04e-05	0.000245	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—GPC3—kidney cancer	5.04e-05	0.000724	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Doxorubicin—kidney cancer	4.98e-05	0.000242	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	4.94e-05	0.000709	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—ITPR2—kidney cancer	4.91e-05	0.000705	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA2—kidney cancer	4.9e-05	0.000704	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SLC2A1—kidney cancer	4.89e-05	0.000702	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.89e-05	0.000702	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—kidney cancer	4.88e-05	0.000237	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—kidney cancer	4.88e-05	0.000237	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—BCHE—kidney cancer	4.86e-05	0.000697	CbGpPWpGaD
Dabigatran etexilate—Constipation—Doxorubicin—kidney cancer	4.84e-05	0.000235	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—MAPK1—kidney cancer	4.8e-05	0.000689	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALAD—kidney cancer	4.78e-05	0.000686	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IGF2—kidney cancer	4.78e-05	0.000686	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPAT—kidney cancer	4.69e-05	0.000673	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GLIPR1—kidney cancer	4.69e-05	0.000673	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	4.69e-05	0.000673	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ST3GAL2—kidney cancer	4.67e-05	0.00067	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.63e-05	0.000664	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—kidney cancer	4.62e-05	0.000225	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.58e-05	0.000658	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2—kidney cancer	4.58e-05	0.000657	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALDH1A1—kidney cancer	4.56e-05	0.000655	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—kidney cancer	4.53e-05	0.000651	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CER1—kidney cancer	4.52e-05	0.000649	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GPC3—kidney cancer	4.52e-05	0.000649	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Doxorubicin—kidney cancer	4.49e-05	0.000218	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—kidney cancer	4.47e-05	0.000217	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—ITPR2—kidney cancer	4.46e-05	0.00064	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	4.43e-05	0.000636	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	4.43e-05	0.000636	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC5A3—kidney cancer	4.37e-05	0.000628	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PGK1—kidney cancer	4.37e-05	0.000628	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—FH—kidney cancer	4.36e-05	0.000626	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APRT—kidney cancer	4.36e-05	0.000626	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—LDHB—kidney cancer	4.29e-05	0.000615	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	4.26e-05	0.000611	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—kidney cancer	4.17e-05	0.000202	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CA—kidney cancer	4.16e-05	0.000598	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	4.15e-05	0.000596	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	4.14e-05	0.000595	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—ANXA1—kidney cancer	4.12e-05	0.000591	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GPC3—kidney cancer	4.1e-05	0.000588	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTP1—kidney cancer	4.08e-05	0.000585	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—JUN—kidney cancer	4.07e-05	0.000584	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Doxorubicin—kidney cancer	4.06e-05	0.000197	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—kidney cancer	4e-05	0.000194	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—CA2—kidney cancer	3.99e-05	0.000572	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	3.89e-05	0.000558	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALAD—kidney cancer	3.88e-05	0.000558	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Doxorubicin—kidney cancer	3.87e-05	0.000188	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—ABCB1—kidney cancer	3.86e-05	0.000554	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SFRP2—kidney cancer	3.84e-05	0.000552	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ST3GAL2—kidney cancer	3.79e-05	0.000544	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	3.76e-05	0.00054	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGF2—kidney cancer	3.76e-05	0.00054	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTM1—kidney cancer	3.75e-05	0.000538	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Doxorubicin—kidney cancer	3.74e-05	0.000182	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—ANXA1—kidney cancer	3.74e-05	0.000536	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA9—kidney cancer	3.72e-05	0.000534	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALDH1A1—kidney cancer	3.71e-05	0.000532	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	3.68e-05	0.000528	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	3.64e-05	0.000522	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—kidney cancer	3.62e-05	0.00052	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	3.61e-05	0.000518	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Doxorubicin—kidney cancer	3.6e-05	0.000175	CcSEcCtD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	3.58e-05	0.000514	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—POMC—kidney cancer	3.57e-05	0.000512	CbGpPWpGaD
Dabigatran etexilate—Rash—Doxorubicin—kidney cancer	3.57e-05	0.000173	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—kidney cancer	3.56e-05	0.000173	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	3.55e-05	0.00051	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP1A1—kidney cancer	3.55e-05	0.00051	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PGK1—kidney cancer	3.55e-05	0.00051	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC5A3—kidney cancer	3.55e-05	0.00051	CbGpPWpGaD
Dabigatran etexilate—Headache—Doxorubicin—kidney cancer	3.54e-05	0.000172	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	3.5e-05	0.000502	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—LDHB—kidney cancer	3.48e-05	0.0005	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	3.48e-05	0.000499	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	3.48e-05	0.000499	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	3.48e-05	0.000499	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—PIK3CA—kidney cancer	3.47e-05	0.000498	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	3.38e-05	0.000485	CbGpPWpGaD
Dabigatran etexilate—Nausea—Doxorubicin—kidney cancer	3.36e-05	0.000163	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—CRABP1—kidney cancer	3.16e-05	0.000454	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	3.1e-05	0.000446	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ACY1—kidney cancer	3.1e-05	0.000445	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKAP13—kidney cancer	3.1e-05	0.000445	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP2—kidney cancer	3.1e-05	0.000445	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—kidney cancer	3.08e-05	0.000442	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	3.04e-05	0.000436	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CA9—kidney cancer	3.02e-05	0.000434	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.95e-05	0.000424	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ITPR2—kidney cancer	2.94e-05	0.000422	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GRB7—kidney cancer	2.83e-05	0.000407	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTT1—kidney cancer	2.68e-05	0.000385	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ACHE—kidney cancer	2.68e-05	0.000385	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—POMC—kidney cancer	2.65e-05	0.00038	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PDHB—kidney cancer	2.64e-05	0.000379	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ITPR2—kidney cancer	2.63e-05	0.000378	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—RAF1—kidney cancer	2.63e-05	0.000378	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CRABP1—kidney cancer	2.57e-05	0.000369	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	2.54e-05	0.000365	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SCARB1—kidney cancer	2.54e-05	0.000364	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS1—kidney cancer	2.51e-05	0.00036	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—POMC—kidney cancer	2.51e-05	0.00036	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CCBL1—kidney cancer	2.48e-05	0.000356	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PSMD7—kidney cancer	2.46e-05	0.000353	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNA1—kidney cancer	2.39e-05	0.000343	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ITPR2—kidney cancer	2.39e-05	0.000343	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EIF4EBP1—kidney cancer	2.37e-05	0.000341	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HSPB1—kidney cancer	2.37e-05	0.000341	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—kidney cancer	2.36e-05	0.000339	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—BCHE—kidney cancer	2.33e-05	0.000335	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC5A5—kidney cancer	2.31e-05	0.000331	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC2A1—kidney cancer	2.23e-05	0.00032	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PSMD7—kidney cancer	2.21e-05	0.000317	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TSC1—kidney cancer	2.21e-05	0.000317	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ANXA1—kidney cancer	2.21e-05	0.000317	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.2e-05	0.000316	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ACHE—kidney cancer	2.18e-05	0.000313	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTT1—kidney cancer	2.18e-05	0.000313	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPAT—kidney cancer	2.15e-05	0.000309	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GLIPR1—kidney cancer	2.15e-05	0.000309	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FLT1—kidney cancer	2.14e-05	0.000307	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—kidney cancer	2.11e-05	0.000303	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SCARB1—kidney cancer	2.06e-05	0.000296	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS1—kidney cancer	2.04e-05	0.000293	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—POMC—kidney cancer	2.02e-05	0.000289	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—kidney cancer	2e-05	0.000288	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PSMD7—kidney cancer	2e-05	0.000287	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APRT—kidney cancer	2e-05	0.000287	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FH—kidney cancer	2e-05	0.000287	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	1.99e-05	0.000286	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PAK1—kidney cancer	1.98e-05	0.000285	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JUNB—kidney cancer	1.98e-05	0.000285	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	1.97e-05	0.000283	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	1.93e-05	0.000277	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—BCHE—kidney cancer	1.9e-05	0.000272	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK3—kidney cancer	1.9e-05	0.000272	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPC3—kidney cancer	1.88e-05	0.00027	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC5A5—kidney cancer	1.87e-05	0.000269	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTP1—kidney cancer	1.86e-05	0.000267	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—kidney cancer	1.84e-05	0.000264	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.84e-05	0.000263	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—POMC—kidney cancer	1.83e-05	0.000263	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA2—kidney cancer	1.83e-05	0.000262	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	1.83e-05	0.000262	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC2A1—kidney cancer	1.81e-05	0.00026	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK1—kidney cancer	1.8e-05	0.000259	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—kidney cancer	1.79e-05	0.000257	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALAD—kidney cancer	1.78e-05	0.000256	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.77e-05	0.000254	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCB1—kidney cancer	1.76e-05	0.000252	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.76e-05	0.000252	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.74e-05	0.00025	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ST3GAL2—kidney cancer	1.74e-05	0.00025	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.74e-05	0.00025	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.73e-05	0.000248	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTM1—kidney cancer	1.71e-05	0.000245	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—kidney cancer	1.7e-05	0.000245	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALDH1A1—kidney cancer	1.7e-05	0.000244	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.68e-05	0.000241	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC5A3—kidney cancer	1.63e-05	0.000234	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PGK1—kidney cancer	1.63e-05	0.000234	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF2—kidney cancer	1.62e-05	0.000233	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP1A1—kidney cancer	1.62e-05	0.000232	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN2B—kidney cancer	1.61e-05	0.000232	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LDHB—kidney cancer	1.6e-05	0.000229	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1R—kidney cancer	1.57e-05	0.000225	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—kidney cancer	1.57e-05	0.000225	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.53e-05	0.00022	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	1.52e-05	0.000218	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—kidney cancer	1.51e-05	0.000217	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—RAF1—kidney cancer	1.51e-05	0.000217	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTP1—kidney cancer	1.51e-05	0.000217	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—kidney cancer	1.49e-05	0.000214	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.44e-05	0.000206	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCB1—kidney cancer	1.43e-05	0.000205	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.4e-05	0.000201	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTM1—kidney cancer	1.39e-05	0.000199	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA9—kidney cancer	1.39e-05	0.000199	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.37e-05	0.000196	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—kidney cancer	1.35e-05	0.000194	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1A1—kidney cancer	1.31e-05	0.000189	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—kidney cancer	1.3e-05	0.000187	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.29e-05	0.000185	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIF1A—kidney cancer	1.29e-05	0.000185	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TSC2—kidney cancer	1.29e-05	0.000185	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KDR—kidney cancer	1.23e-05	0.000177	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—POMC—kidney cancer	1.21e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.19e-05	0.00017	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CRABP1—kidney cancer	1.18e-05	0.000169	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.15e-05	0.000165	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KIT—kidney cancer	1.14e-05	0.000163	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APC—kidney cancer	1.14e-05	0.000163	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ITPR2—kidney cancer	1.1e-05	0.000157	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK3—kidney cancer	1.09e-05	0.000156	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—POMC—kidney cancer	1.08e-05	0.000155	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.08e-05	0.000155	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BRAF—kidney cancer	1.07e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK1—kidney cancer	1.04e-05	0.000149	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTT1—kidney cancer	9.99e-06	0.000143	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ACHE—kidney cancer	9.99e-06	0.000143	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—kidney cancer	9.89e-06	0.000142	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—POMC—kidney cancer	9.8e-06	0.000141	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—kidney cancer	9.78e-06	0.00014	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—kidney cancer	9.62e-06	0.000138	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SCARB1—kidney cancer	9.46e-06	0.000136	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS1—kidney cancer	9.36e-06	0.000134	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PSMD7—kidney cancer	9.18e-06	0.000132	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—kidney cancer	8.98e-06	0.000129	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RAF1—kidney cancer	8.92e-06	0.000128	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RELA—kidney cancer	8.88e-06	0.000127	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—kidney cancer	8.82e-06	0.000127	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MTOR—kidney cancer	8.71e-06	0.000125	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BCHE—kidney cancer	8.7e-06	0.000125	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC5A5—kidney cancer	8.6e-06	0.000123	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—kidney cancer	8.39e-06	0.00012	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC2A1—kidney cancer	8.3e-06	0.000119	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—kidney cancer	8.17e-06	0.000117	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—kidney cancer	8e-06	0.000115	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	7.92e-06	0.000114	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—kidney cancer	7.82e-06	0.000112	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—kidney cancer	7.79e-06	0.000112	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JUN—kidney cancer	7.78e-06	0.000112	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—kidney cancer	7.72e-06	0.000111	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—kidney cancer	7.52e-06	0.000108	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTP1—kidney cancer	6.92e-06	9.94e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—kidney cancer	6.82e-06	9.79e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—kidney cancer	6.8e-06	9.75e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK3—kidney cancer	6.43e-06	9.23e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTM1—kidney cancer	6.36e-06	9.13e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—kidney cancer	6.25e-06	8.98e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK1—kidney cancer	6.12e-06	8.78e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1A1—kidney cancer	6.03e-06	8.66e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—kidney cancer	5.92e-06	8.5e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—kidney cancer	5.78e-06	8.29e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—kidney cancer	5.31e-06	7.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—kidney cancer	5.13e-06	7.37e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—kidney cancer	4.81e-06	6.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—POMC—kidney cancer	4.5e-06	6.46e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—kidney cancer	3.59e-06	5.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—kidney cancer	3.13e-06	4.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—kidney cancer	2.21e-06	3.17e-05	CbGpPWpGaD
